Latest Breaking News On - What we do not know - Page 1 : comparemela.com
BURLINGTON, Mass., August 04, 2023 PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the publication of a cost-effectiveness analysis of ropeginterferon alfa-2b-njft (marketed as BESREMi®) in the Journal of Comparative Effectiveness Research. The analysis, titled "Cost-Effectiven
United-statesJapanSouth-koreaTaiwanChinaTaipeiT-ai-peiTaiwaneseAmericanRaymond-urbanskiPharmaessentia-tpexAaron-gerds